2015: Kassy Perry, speaking on behalf of ?, opposing AB 463, on transparency of drug R&D costs and subsidies

During the debate of California bill AB 463, on the Pharmaceutical Cost Transparency Act of 2015, Kassy Perry was using Twitter to attack the bill, posting links to and repeating pharmaceutical industry talking points. Who is Kassy Perry? A founder of Perry Communications, a Sacramento public relations and lobbying firm. This is her Twitter profile:

https://twitter.com/KassyPerry

Continue Reading

Sony referred to “WIPO treaty for blind as “stalking horse” to “denigrate the rights of copyright owners”

In the new Wikileaks archives of leaked Sony documents (Link here), there is a memo (https://wikileaks.org/sony/docs/05/docs/DECE/DECE%20CP1%20-%20ss.doc.pdf), which describes Sony Pictures Entertainment (SPE) concern over the proposed WIPO treaty for copyright exceptions for persons who are blind or have other disabilities. The memo, undated in the Wikileaks archives, but probably written in 2009, included the following passages:

Continue Reading

Patents with government interests, by disease, 2010 to 2013

The attached PDF file provides counts on the number of patents with various search terms in the specification (spec/”search term”), and the number of those patents that declare either government rights in the patents (govt/government), an assignment to the US government (an/”united states of america”), or both. The complete counts are in the PDF file. The queries were done by Claire Cassedy on December 5, 2014.

Continue Reading

Comments to USTR on the Out-of-Cycle Review for India due October 31, 2014.

Continue Reading

Uncategorized

Money speaks: USTR releases letters from Congress backing PhRMA on exclusive rights biologic test data in TPP

As part of a partial response to FOIA request, USTR has provided KEI with copies of 13 letters sent by members of Congress, from July 27, 2011 to August 8, 2013, on the topic of biologic drug test data provisions in the TPP negotiation. We had obtained several but not all of these letters earlier from a variety of sources, including from PhRMA’s web page — where some had been proudly displayed. (See link below).

Were there letters on the other side? Yes, three. (see below).

With the FOIA request, we have also obtained the responses to the letters.

Continue Reading

Uncategorized

KEI’s comments on Special 301, March 7, 2014

KEI’s Additional Comments Special 301

March 7, 2014

James Love, Knowledge Ecology International

Docket # USTR-2013-0040

These comments supplement KEI’s February 7, 2014 written submission (Also available here: https://www.keionline.org/ustr/special301, and /node/1927), and our February 24, 2014 oral testimony, and provide also comment or reply to the written or oral submissions by others.

1. India is an important source of affordable medicines.

Continue Reading

Uncategorized
© 2025 Knowledge Ecology International. All rights reserved.
Hiero by aThemes
michael_froman.png
Ambassador Michael Froman wants to block compulsory licenses on drug patents in India